The increasing burden of noncommunicable diseases has led to an epidemic of heart failure (HF) and diabetes mellitus globally. [1] [2] [3] [4] The prevalence of comorbid diabetes among hospitalized HF patients has increased and now exceeds 40%. [5] [6] [7] The term diabetic cardiomyopathy has been suggested for HF without evidence of epicardial disease or long-standing hypertension. 8 When both conditions coexist, the optimal strategies to improve health status, resource utilization, and outcomes are an area of active discovery. Diabetes and HF require frequent monitoring, significant lifestyle modifications, and multiple classes of medications for patients and physicians to navigate.
Among patients with atherosclerotic cardiovascular disease, the presence of comorbid diabetes increases the risk of adverse events and incident HF. 9 How diabetes may interact with treatment strategies and contribute to additional long-term risks for HF patients is not well characterized in clinical practice. Understanding the interactions between these 2 common comorbidities in the clinical practice setting is critical for tailoring both acute and chronic management to achieve patient-centered goals. In addition, diabetes may influence morbidity and mortality risk among patients with HF with reduced (HFrEF), borderline (HFbEF), and preserved ejection fraction (HFpEF) differently, yet this has not been well studied.
The purpose of this analysis was to understand the longterm outcomes for patients with HF with and without diabetes, further stratified by ejection fraction. Using the Get With The Guidelines (GWTG)-HF Registry linked to Centers for Medicare & Medicaid Services (CMS) claims data, we evaluated clinical differences and outcomes between patients with and without diabetes and a primary discharge diagnosis of HFrEF, HFbEF, or HFpEF.
Methods

Study cohort
The study cohort was obtained from GWTG-HF, a national prospective HF registry and quality improvement program sponsored by the American Heart Association (AHA). Details of the design and conduct of the GWTG-HF registry have been previously described. 10, 11 Patients discharged between January 1, 2006, and November 30, 2014, were screened for inclusion. All patients included in the GWTG-HF registry have been identified by physicians based on clinically diagnosed HF admission. Inclusion into the cohort required CMS claims linkage. Patients were excluded if they were not using fee-for-service Medicare at the month of index discharge, died during index hospitalization, were comfort care only, left against medical advice, were discharged to a short-term hospital, were discharged to hospice, or were missing left ventricular ejection fraction (LVEF) or medical history data.
Outcomes
Primary outcomes of interest were all-cause mortality and readmissions at 3 years after index discharge. Mortality was ascertained using CMS denominator file. Secondary outcomes of interest included cardiovascular readmission and major cardiovascular composite events defined by all-cause mortality or cardiovascular readmission. Cardiovascular readmissions included primary discharge diagnosis HF, acute coronary syndromes, ischemic stroke, and hemorrhagic stroke (Table I in Covariates HF subtypes were defined by LVEF quantitative assessment criteria consistent with society guideline definitions: HFrEF, ≤40%; HFbEF, N40% and b50%; and HFpEF, ≥50%.
12,13 Demographics included age, sex, and race/ ethnicity. Abstracted medical histories from GWTG-HF include anemia, atrial arrhythmia, ventricular arrhythmia, chronic obstructive pulmonary disease, chronic renal insufficiency, coronary artery disease/ischemic heart disease, depression, diabetes mellitus, ischemic history, smoking history, hyperlipidemia, hypertension, and peripheral vascular disease. A new diagnosis of diabetes was based on patients without past medical history of diabetes that was newly diagnosed during the index HF hospitalization. Clinical measurements included admission and discharge vital signs, routine laboratory test results, and discharge medication lists. Hospital factors included bed size, teaching status, region, and rural/urban location.
Statistical analysis
Baseline patient and hospital characteristics were described by diabetes status and stratified by HF subtype: HFrEF, HFbEF, and HFpEF. Percentages, means with SDs, and medians with interquartile ranges (IQRs) were reported for categorical and continuous variables, respectively. Standardized differences for characteristics between patients with and without diabetes were estimated.
Kaplan-Meier estimates were made for 3-year all-cause readmission and mortality end points. A Cox proportionalhazard model was used for the primary and secondary outcomes. Cox proportional models were adjusted for baseline patient and hospital characteristics. Control variables were selected based on a literature review and prior established models used in GWTG-HF. [14] [15] [16] Random effects were used to adjust for clustering at the hospital level. Lack-of-fit tests were used to evaluate continuous covariates. Splines were used for select variables with nonlinear relationships on the hazards of interest. Multiple imputation was used for missing variables other than medical history and hospital characteristics. Variables with N35% missing were excluded from the models. Interactions were tested between diabetes status and select patient characteristics for the primary outcomes. Statistical significance was defined for values equal to or less than P = .05. Analyses were performed in SAS software version 9.4 (SAS Institute, Inc, Cary, NC).
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Results
The final cohort included 89,659 patients from 417 sites (Table II in the Supplementary Data). An additional cohort to evaluate competing risk for 30-day end points secondary to inpatient mortality was defined with prespecified exclusions after day of admission (Table III in the Supplementary Data). Inpatient rates of mortality were lower among diabetic patients across HF categories and did not influence 30-day event reporting (Table IV in the Supplementary Data). The most common subtype of HF discharged was HFpEF (48.2%) followed by HFrEF (42.2%) and HFbEF (9.6%), and 39.9% had prevalent or incident comorbid diabetes (Table V , A and V, B in the Supplementary Data). Across all HF subtypes, patients with diabetes were a few years younger on average and had more ischemic heart disease, prior strokes, hypertension, and renal insufficiency (Table I ). There were key differences by sex: patients with HFrEF were predominately male (59.4%), patients with HFbEF were sex balanced (female 49.7%), and patients with HFpEF were predominately female (66.2%). Patients with diabetes were more likely to receive statin therapy. Standardized differences for baseline characteristics are provided (Table VI in the Supplementary Data) Unadjusted all-cause mortality rates at 30 days postdischarge were between 4.4% and 5.8% (Table II and Figures 1, 2, and 3) . Readmission rates at 30 days were around 22% for patients with diabetes and 20% for patients without diabetes. Among patients with HFrEF, diabetes conferred a 27% (95% CI 7%-49%, P = .0051) greater adjusted hazard of all-cause mortality and 22% greater hazard for major adverse cardiac event (95% CI 7%-39%, P = .0024) compared with patients with no diabetes at 3 years of observation (Table III) . Among HFbEF patients, diabetes did not seem to contribute an additional mortality risk; however, the all-cause readmission hazard was 48% (95% CI 15%-90%, P = .0023) greater for patients with diabetes, and cardiovascular readmission was 59% greater (95% CI 18%-116%, P = .0026) (See Table III and Figure 2) . Among HFpEF patients, diabetes status was not associated with greater mortality or readmission risk that was statistically significant. (See Table III and Figure 3) .
Interactions between diabetes and additional patient characteristics were tested. Among patients with HFrEF, women had a higher risk for mortality relative to men (P for interaction = .0195) (Table IVA) . Additionally, white and Asian patients had worse outcomes with diabetes relative to African Americans and Hispanics (P for interaction = .0031). For patients with HFpEF, diabetes was a greater risk factor among those younger than 75 years (P for interaction = .0270).
With respect to the all-cause readmission end point, diabetes was a greater risk among those younger than CV, cardiovascular; MACE, major adverse cardiac events (composite of all-cause mortality and cardiovascular readmission).
75 years (P for interaction = .0501) for HFrEF patients (  Table IVB) . For HFbEF and HFpEF patients, female patients with diabetes were at greater risk for readmission (P for interaction = .0096 and .0075). Among HFpEF patients, white and Asian patients had greater readmission risk related to the presence of diabetes (P for interaction = .0153).
Discussion
This large study describes the clinical characteristics and long-term outcomes of patients hospitalized for HF with and without diabetes. The analysis was stratified by HF subtype to evaluate the differential associations of diabetes status with long-term outcomes. Overall, we find that HF patients with diabetes are younger and more likely to have ischemic heart disease and additional comorbidities. While controlling for baseline factors and comorbidities, we find that diabetes is independently associated with an additional mortality and readmission risk for HFrEF patients. Among HFbEF and HFpEF patients, diabetes has no appreciable association with all-cause mortality but is associated with substantially higher readmission risk for HFbEF patients. Among HFpEF patients, diabetes status does not appear to be associated with additional mortality risk but may be associated with a higher risk of cardiovascular readmission.
Prior research has shown that a hospitalized patient's diabetes status may influence inpatient mortality risk, although a prior study from OPTIMIZE-HF found no association of diabetes with in-hospital or 60-to 90-day Figure 1 Kaplan-Meier curves for HFrEF for all-cause mortality and all-cause readmission by diabetes status. ⁎ Adjusted patient and hospital characteristics as listed in the "Methods" section.
mortality rates. 5, 17 For HFrEF patients, a secondary analysis of the PARADIGM-HF trial showed that diabetes and hemoglobin A1C (HbA1C) level were associated with a significantly higher hazard for both mortality and hospitalizations after a median follow-up of 26 months. 18 Similar findings were seen among diabetes patients with ischemic HFrEF in the EPHESUS trial. 19 Although our findings are not stratified by HbA1C levels, the risk we present is consistent with prior findings among HFrEF patients.
When accounting for other comorbidities, diabetes is a risk factor for incident HFpEF and theorized to contribute to disease severity. 20, 21 Secondary analyses of older multinational randomized controlled trials that recruited patients with HFpEF have estimated significant hazards for all-cause mortality and readmission secondary to comorbid diabetes. [22] [23] [24] [25] These reported GWTG-HF longterm outcomes did not reflect a significant risk differential related to comorbid diabetes for patients with HFpEF in a much larger US Medicare population when controlling for other clinical and hospital factors. The differences between these findings and the prior literature may relate to the older age of GWTG-HF cohort and higher baseline event rates for both populations with Kaplan-Meier curves for HFbEF for all-cause mortality and all-cause readmission by diabetes status.
Figure 3
Kaplan-Meier curves for HFpEF for all-cause mortality and all-cause readmission by diabetes status. and without diabetes. Additionally, GWTG-HF is a US rather than multinational cohort where systems of care and treatment strategies for both HF and diabetes may differ. The GWTG-HF cohort had higher rates of comorbid conditions compared to the relatively healthier HFpEF cohorts recruited to multinational clinical trials. Therefore, as an isolated risk factor among many, the impact of diabetes may not have been as perceptible. The adjusted statistical models included both hospital and clinical factors that may not have been adjusted in the prior work and confounded prior associations with diabetes. Given the lack of evidence-based treatment strategies for HFpEF, these results may reflect the inability to improve outcomes once hospitalized for symptomatic HFpEF with current management strategies. The application of novel drug classes to the HFpEF patient population may help address major treatment gaps. The upcoming PARAGON-HF trial using sacubitril/valsartan and SGLT2 inhibitor trials will evaluate improvements in clinical outcomes for patients with HFpEF. 26, 27 Despite the smaller sample size, among HFbEF patients, we find a strong association with increased readmission risk among patients with diabetes without a clear mortality risk after adjusting for other comorbidities. Diabetes may be associated with greater severity of HF symptoms and difficulty with volume regulation given the higher risk of cardiovascular specific readmission. Diabetes imparts observable metabolic shifts that contribute to myocardial dysfunction and fluid balance. Insulin resistance results in increased free fatty acid metabolism and decreased glycolysis in the myocyte leading to increased oxidative stress and mitochondrial dysfunction. 28 Diabetes may also be a marker for other unmeasured patient factors not adjusted for in the hazard model that predispose these patients to increased inpatient utilization.
Secondary analyses from the EMPA-REG Outcome trial found that both the risk for HF hospitalization and cardiovascular death were reduced with SGLT-2 inhibition among patients with and without HF. 29 A 39% reduction in hazard was noted for hospitalization or death from HF. There were also improvements in HF-related outcomes in the CANVAS trials. Given the lack of evidence for other hyperglycemic medication classes in reducing cardiovascular or mortality outcomes, SGLT2 inhibitors should be given consideration for HF patients with diabetes of all subtypes without contraindications to treatment. The Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial will be further evaluating the effect of an SGLT-1/ 2 inhibitor on outcomes in patients hospitalized with HF (ClinicalTrials.gov Identifier: NCT03521934).
Limitations
These data are from patients with Medicare insurance and hospitals participating in GWTG-HF and may not apply to patients and care settings that substantially differ. Diabetes status was ascertained primarily based on clinical chart abstraction definitions for patients participating in the GWTG-HF registry, and some patients may have had undiagnosed diabetes and been misclassified. We did not attempt to model severity of diabetes based on HbA1C levels, as nearly 90% did not have these laboratory values available on index admission. We also did not consider the severity of diabetes based on the duration of diabetes or number of hyperglycemic medications. The younger age of patients with diabetes patients suggests an overall survival bias for nondiabetes patients with HF; therefore, the risks related to comorbid diabetes are likely underappreciated from the population perspective. Residual measured and unmeasured confounding may have influenced the findings.
Conclusion
HF patients with HFrEF and HFbEF aged 65 years or older with diabetes are at increased risk for mortality and rehospitalization after an index hospitalization, independent of patient and hospital characteristics. Diabetes does not appear to be associated with significant additional risk among patients with HFpEF when adjusting for other known patient and hospital characteristics. The increasing prevalence of diabetes nationally overall and among HF patients is a cause for alarm and a complicating factor in other severe chronic diseases. Public health interventions are desperately needed to stem the tide of both diabetes and HF. Diabetes imparts differential trajectories and risk of mortality and readmission depending on the subtype of HF based on LVEF assessment. Given the elevated rates of mortality and rehospitalization among these HF patients, identification of treatment strategies and novel therapeutics is needed to improve further patient outcomes with HF and diabetes.
